Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW1807 vs DW1807-R2 in Perennial Allergic Rhinitis with Asthma
NCT07168473Phase 3Recruiting
- Sponsor
- Daewon Pharm
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of DW1807 in perennial allergic rhinitis (PAR), asthma, sponsored by Daewon Pharm. Started Sep 2024; status: recruiting.
02
Drugs
DW1807
03
Conditions
perennial allergic rhinitis (PAR)asthma
Beyond the preview
Go deeper on NCT07168473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168473.